Kala Pharmaceuticals (ISIN: US4831191000) has entered voluntary liquidation, marking the end of its public trading journey on Nasdaq. US investors holding shares must act swiftly as delisting and cash distribution loom, with implications for biotech portfolios amid a challenging funding environment. Here’s what happened, why it matters now, and next steps for shareholders.
Kala Pharmaceuticals stock has reached a critical juncture. The Waltham, Massachusetts-based biotech company announced on March 11, 2025, that it would voluntarily delist its common shares from the Nasdaq Global Market and enter into an Assignment for the Benefit of Creditors (ABC) process, effectively leading to liquidation. This move came after years of clinical…